Research programme: sexual dysfunction therapy - Palatin Technologies

Drug Profile

Research programme: sexual dysfunction therapy - Palatin Technologies

Alternative Names: PL-6983

Latest Information Update: 03 Jul 2012

Price : $50

At a glance

  • Originator Palatin Technologies
  • Class Peptides
  • Mechanism of Action Melanocortin type 1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Erectile dysfunction; Female sexual dysfunction

Most Recent Events

  • 03 Jul 2012 Preclinical development is ongoing in the US
  • 13 May 2008 Preclinical trials in Erectile dysfunction in USA (unspecified route)
  • 13 May 2008 Preclinical trials in Female sexual dysfunction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top